Literature DB >> 719601

24-hour infusion of cis-platinum in head and neck cancers.

C Jacobs, J R Bertino, D R Goffinet, W E Fee, R L Goode.   

Abstract

Eighteen patients with advanced squamous cell cancer of the head and neck were treated with cis-diamminedichloroplatinum in a 24-hour infusion. The most frequent dose used was 80 mg/m2 repeated every three weeks. Six were treated preoperatively for Stage III or IV disease, and twelve were treated for recurrent disease. The overall response rate was 72% with one complete remission, greater than 50% regression in six patients, and 25--50% regression in six patients. Toxicity was minimal: creatinine greater than 2 in 6% of courses, leukopenia in 9%, anemia in 29%, vomiting in 76%, and documented minimal hearing loss in one patient. Plasma and urine platinum levels during infusion are presented. The dosage of 80 mg/m2 administered over 24 hours gives a response rate in head and neck cancers equivalent to that reported with higher doses given by rapid infusion, and toxicity is minimal.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 719601     DOI: 10.1002/1097-0142(197811)42:5<2135::aid-cncr2820420508>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.

Authors:  N J Petrelli; S Madejewicz; Y Rustum; L Herrera; P J Creaven; J Plager; J Soloman; A Mittelman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

4.  Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas.

Authors:  M Jäckel; P Köpf-Maier
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.

Authors:  R Parti; W Wolf
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.

Authors:  J D Holding; W E Lindup; C van Laer; G C Vreeburg; V Schilling; J A Wilson; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

7.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  High-dose cisplatin in advanced head and neck cancer.

Authors:  A A Forastiere; B J Takasugi; S R Baker; G T Wolf; V Kudla-Hatch
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment.

Authors:  Loredana G Marcu; E Yeoh
Journal:  J Cancer Res Clin Oncol       Date:  2009-07-30       Impact factor: 4.553

10.  A phase I trial of 5-day continuous infusion cisplatin and interferon alpha.

Authors:  M P Gosland; S Goodin; R A Yokel; M Smith; W J John
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.